Distinct Features of Chip–Derived and De Novo MDS

@inproceedings{Nagata2018DistinctFO,
  title={Distinct Features of Chip–Derived and De Novo MDS},
  author={Yasunobu Nagata and Hideki Makishima and Cassandra M. Hirsch and Hassan Awada and Abhinav Goyal and Teodora Kuzmanovic and Bartlomiej P Przychodzen and Tetsuichi Yoshizato and Kenichi Yoshida and Kenichi Chiba and Hiroko Tanaka and Yuichi Shiraishi and Satoru Miyano and Sudipto Mukherjee and Tomas Radivoyevitch and Thomas LaFramboise and Aziz Nazha and Mikkael A. Sekeres and Torsten Haferlach and Seishi Ogawa and Jaroslaw P. Maciejewski},
  year={2018}
}
Subclinical clonal expansions, referred to as clonal hematopoiesis of indeterminate potential (CHIP), are present in blood of otherwise healthy individuals and their frequency increases with age. While many CHIP-associated mutations are present in MDS, only a small proportion of asymptomatic individuals with CHIP progress to MDS. We assumed that: i) a proportion of CHIP mutations will eventually serve as ancestral hits that manifest as MDS upon acquisitions of additional genetic alterations… CONTINUE READING

Topics from this paper.